An Open-Label, Escalating Dose, Single Center, Cross-Over Design, Phase I Study to Evaluate Menses Induction in Women Administered Proellex.
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2014
At a glance
- Drugs Telapristone (Primary)
- Indications Menstruation disorders
- Focus Pharmacodynamics
- Sponsors Repros Therapeutics
- 12 Feb 2010 Actual patient number (11) added as reported by ClinicalTrials.gov.
- 12 Aug 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 03 Aug 2009 Status changed from active, no longer recruiting to suspended, according to a Repros Therapeutics media release.